Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07203391 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

Study acronym: TRIUMPH
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date changed from estimate of Dec 1, 2025 to Feb 1, 2026v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a combination study of Tebentafusp and the PI3Kdelta inhibitor, Roginolisib
Trial Details
NCT Number NCT07203391
Lead Sponsor St Vincent's Hospital, Sydney
Conditions
(from sponsor)		 Uveal Melanoma, Metastatic
Related terms Neoplasm Metastasis, Uveal Melanoma
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov